A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis Patients

ovartis Pharmaceuticals0 个研究点目标入组 4 人开始时间: 2022年8月12日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Subjects have diagnosis of primary myelofibrosis (PMF) according to the 2016 World Health Organization (WHO) criteria, or diagnosis of post-essential thrombocythemia (ET) (PET-MF) or post-polycythemia vera (PV) myelofibrosis (PPV-MF) according to the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) 2007 criteria
•- Palpable spleen of at least 5 cm from the left costal margin (LCM) to the point of greatest splenic protrusion or enlarged spleen volume of at least 450 cm3 per MRI or CT scan at baseline (a MRI/CT scan up to 8 weeks prior to first dose of study treatment can be accepted).
•- Have been treated with ruxolitinib for at least 24 weeks prior to first dose of study treatment
•- Are stable (no dose adjustments) on the prescribed ruxolitinib dose (between 5 and 25 mg twice a day (BID)) for = 8 weeks prior to first dose of study treatment

•- Not able to understand and to comply with study instructions and requirements.
•- Received any investigational agent for the treatment of MF (except ruxolitinib) within 30 days of first dose of study treatment or within 5 half-lives of the study treatment, whichever is greater
•- Peripheral blood blasts count of > 10%.
•- Received a monoclonal antibody (Ab) or immunoglobulin-based agent within 1 year of screening, or has documented severe hypersensitivity reactions/immunogenicity (IG) to a prior biologic
•- Splenic irradiation within 6 months prior to the first dose of study drug
•- Received blood platelet transfusion within 28 days prior to first dose of study treatment.

发起方

ovartis Pharmaceuticals